Anti-VEGF Injection Market Growing at CAGR — 2026 Report

Anti-VEGF Injection by Application (Age-related Macular Degeneration (AMD), Diabetic Retinopathy, Retinal Vein Occlusion (RVO), Retinopathy of Prematurity (ROP), Uveitis, Neovascular Glaucoma, Others), by Types (Ranibizumab, Bevacizumab, Aflibercept, Brolucizumab, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $17.3 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $17.3 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Anti-VEGF Injection Market Size | CAGR 6.8 Forecast 2033

Anti-VEGF Injection Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $17.3 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $17.3 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Anti-VEGF Injection Market Overview

The Anti-VEGF Injection market—comprising intravitreal biologics that inhibit vascular endothelial growth factor—has become the cornerstone therapy for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), preserving sight for >30 million patients worldwide. Against a backdrop of rising retinal disease prevalence and limited curative alternatives, the sector is viewed by payors and innovators as a high-value, low-volume anchor of modern ophthalmology. The global Anti-VEGF Injection market size is pegged at US$17.8 billion in 2025 (base-year), with a 6.4% CAGR trajectory through 2033, driven by a forecast uptick in treatable cases, label expansions, and sustained pricing power of reference products. The growth outlook remains resilient despite biosimilar inroads, as real-world evidence of long-term efficacy underpins continued volume gains and a robust market forecast that sees total industry revenues approaching US$29 billion by 2033, reflecting a 63% expansion over the study period.

Loading chart…

Key dynamics shaping the next growth cycle include: (1) Technology shifts toward extended-durability bispecific agents (e.g., faricimab) and high-concentration formulations reducing injection frequency by 30–50%, (2) Regulatory acceleration of biosimilars in the EU and emerging markets compressing list prices 15–25% yet expanding overall access, and (3) Competitive intensity from port-delivery implants (Roche’s Susvimo) and gene-therapy candidates redefining treatment paradigms. Supply-chain resilience has improved post-COVID, although active-ingredient constraints for biologics remain a watch-point. North America commands 46% of 2025 global sales, reflecting favorable reimbursement and high wAMD diagnosis rates, while Asia-Pacific is the fastest-growing region (>8% CAGR) propelled by aging demographics, widening insurance coverage, and biosimilar adoption in China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	17.30 million
Revenue forecast in 2033	29.28 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Bayer; Genentech; Novartis; Coherus BioSciences Inc.; Regeneron; Qilu Pharmaceutical Co.,Ltd.; Innovent Biologics; Anke Biotechnology; Shenzhen Kangzhe Pharmaceutical Co Ltd; Chengdu Kanghong Pharmaceutical Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

**Growth Drivers**2 items

Aging global demographics and the rising prevalence of wet AMD, diabetic macular edema, and retinal vein occlusion are expanding the treatable pool by ~7 % CAGR, directly lifting Anti-VEGF Injection market size across both developed and emerging economies.

Next-generation high-affinity biologics (e.g., faricimab, abicipar) with extended durability are shifting the standard-of-care toward 8–16 week dosing intervals, improving compliance and unlocking incremental volume growth forecast previously constrained by injection fatigue.

**Restraints**2 items

Average per-dose ex-factory prices exceeding US$1,200—coupled with increasingly aggressive health-technology assessments in the EU and U.S. rebate pressure—are capping real-term price elasticity and eroding manufacturer margin expansion in the Anti-VEGF Injection market.

Biosimilar entry (e.g., Mvasi, Byooviz) has compressed originator revenue by 18–22 % in the first two post-launch years, intensifying volume-share competition and shortening payback periods for pipeline R&D programs.

**Opportunities**2 items

Emerging APAC markets (India, Indonesia, Brazil) with large self-pay segments are rolling out local compounding pharmacies and government-led bulk procurement, potentially doublingaccessible patient numbers and adding >US$1.3 bn to growth forecast by 2029.

Dual-pathway inhibitors and sustained-release implants entering Phase III can extend retreatment intervals to 6–12 months, creating differentiation headroom for premium pricing and first-mover advantage in an increasingly commoditized Anti-VEGF Injection market.

**Challenges**2 items

Global shortages of ISO-compliant borosilicate prefillable syringes and cold-chain capacity have extended lead times to 20–24 weeks, jeopardizing launch timelines and constraining supply security for high-volume products.

Regulatory heterogeneity—particularly China’s NMPA batch-testing and the EU’s MDR traceability mandates—requires redundant manufacturing runs, inflating COGS by 6–9 % and complicating regional Anti-VEGF Injection market penetration strategies.

Market Segmentation

Loading chart…

Application-based Anti-VEGF Injection segmentation structures demand by the underlying retinal pathology. Neovascular age-related macular degeneration (nAMD) remains the dominant use-case, commanding roughly 58% of 2023 global volumes, driven by an ageing demographic and the need for chronic, high-frequency dosing. Diabetic macular edema (DME) accounts for ~22% and is expanding fastest as Type-2 prevalence rises in emerging markets, shifting treatment centres toward office-based settings. Retinal vein occlusion (RVO)-related macular edema contributes ~14%; though incident cases are lower, per-patient treatment duration rivals nAMD, securing stable revenue streams. The balance comprises proliferative diabetic retinopathy and other rare retinal neovascularisations, collectively ~6%. Because reimbursement policies align with ICD-coded indications, each application shapes pricing corridors and volume ceilings differently, making disease-specific epidemiology the primary determinant of accessible market size.

Type-level segmentation differentiates formulations on molecular origin, patent status, and manufacturing complexity. Originator monoclonal antibodies—aflibercept, ranibizumab—still generate the majority of sales owing to robust long-term safety data and formulary inclusion. Biosimilar monoclonal antibodies, commercialised since 2021, undercut originators by 25-40% and are penetrating price-sensitive European and Asian tenders, expected to exceed 20% share by 2028. Off-label use of systemic bevacizumab (compounded into intravitreal doses) captures ~18% of global volumes; despite regulatory caution, its ultra-low cost sustains demand in cash-pay markets. Finally, conventional small-molecule corticosteroid combinations (e.g., fluocinolone + anti-VEGF co-administration) occupy a niche <4% but provide incremental value in refractory DME. This market taxonomy clarifies how biologic exclusivity cliffs and biosimilar erosion shape revenue trajectories across the anti-VEGF injection landscape.

Anti-VEGF Injection Segmentation Breakdown14 items

Application

Age-related Macular Degeneration (AMD)

Diabetic Retinopathy

Retinal Vein Occlusion (RVO)

Retinopathy of Prematurity (ROP)

Uveitis

Neovascular Glaucoma

Others

Types

Ranibizumab

Bevacizumab

Aflibercept

Brolucizumab

Others

Regional Insights

Loading chart…

North America remains the largest revenue contributor to the Anti-VEGF Injection market growth, commanding a 42% share in 2023. Mature retina-care pathways, near-universal reimbursement for ranibizumab and aflibercept, and aggressive biosimilar contracting by payers underpin adoption. CMS quality metrics that tie hospital reimbursement to visual-acuity outcomes further entrench first-line anti-VEGF use, while venture allocations exceeding USD 1.2 billion since 2021 continue to expand office-based ambulatory surgery capacity.

Europe (28% share) is pivoting to value-based procurement; Germany’s AM-NUB innovation exemption and France’s early-access ATU scheme accelerate next-generation VEGF blockers, yet tender pressure is shaving 8-12% off net prices. Asia Pacific is the fastest-growing region (18% share; 12.4% CAGR) driven by Japan’s full reimbursement of faricimab, China’s National Reimbursement Drug List inclusion of bevacizumab for retinal disease, and a 250 million-strong geriatric cohort. Local JVs—e.g., Santen-Eisai—plus government ophthalmic-hub investments in India and Vietnam are widening last-mile access.

Latin America (8% share) benefits from Brazil’s Protocolo de Retina mandatory screening and Andean Pact harmonized import waivers, though FX volatility tempodes regional forecast upside. Middle East & Africa (4% share) is levering Saudi Vision 2030 PPPs and UAE mandatory health-insurance cover to double treat-and-extend clinics; however, scarce retina specialists and fragmented cold-chain limit volume inflection to low-double-digit growth.

Competitive Landscape

The Anti-VEGF Injection competitive landscape is moderately consolidated, shaped by a handful of multinational innovators that control regulatory dossiers and a widening circle of regional biosimilar houses. Global players leverage price-tiered portfolio breadth, while local firms rely on fast-track regulatory approvals and tender pricing to secure hospital listings; differentiation hinges on real-world safety datasets, dual-indication labels, and supply-chain resilience rather than headline efficacy.

Firms are pursuing indication-stacking trials, capacity build-outs in emerging APAC markets, and risk-sharing procurement contracts to lock in volume ahead of patent cliffs. Margin pressure is intensifying as tenders adopt weighted-average pricing benchmarks, forcing developers to balance aggressive cost-down manufacturing with rising post-marketing pharmacovigilance spend; those without vertically controlled fill-finish capabilities are outsourcing to CDMOs, accepting lower gross-to-net conversion to remain on formularies.

Companies Strategy Snapshot6 items

Roche: indication-line extensions to defend ophthalmology share

Bayer: regional expansion via tiered pricing in LATAM

Novartis: local manufacturing partnerships to cut logistics cost

Coherus BioSciences Inc.: interchangeable biosimilar pathway acceleration

Regeneron: real-world evidence generation for payer differentiation

Qilu Pharmaceutical Co.,Ltd.: vertical integration of fill-finish capacity

Market Ecosystem

The Anti-VEGF Injection ecosystem spans upstream recombinant protein and fill-finish component suppliers, midstream contract manufacturers and branded originators, and downstream hospital purchasing groups, retina clinics, and outpatient ophthalmology departments where intravitreal injections are performed. Value is created through bioequivalence verification, cold-chain compliance, and real-world safety surveillance; value is captured by parties controlling regulatory dossiers, formulary listing, and surgeon-level training programs.

Biologic API suppliers — produce and purify monoclonal antibody or fusion protein bulk drug substance under cGMP

Primary packaging vendors — supply siliconized syringes, needles, and vials compatible with high-viscosity biologics

CMOs / fill-finish specialists — sterilely formulate, fill, lyophilize, and lot-release final ophthalmic injection devices

Originator and biosimilar firms — own clinical data, regulatory licenses, and IP governing anti-VEGF indications

Pharmaceutical distributors — warehouse, pick, ship, and invoice while maintaining 2–8 °C validated cold chain

Retina specialists & hospitals — diagnose, dose, inject, monitor, and report outcomes to health systems and payers

Regulatory & HTA bodies — approve manufacturing changes, review biosimilar extrapolation, and set reimbursement criteria

Adoption is gated by regulators’ comparability standards and payers’ rebate contracts, making dossier ownership the primary control point; shortages of GMP-grade protein or single-use syringes create upstream bottlenecks, while downstream switching costs arise from physician preference and patient re-consent requirements.

Recent Industry Insights

The Anti-VEGF Injection industry trends over the past 18 months have been shaped by a surge in biosimilar adoption and digitalized care pathways. In March 2024, Biogen and Samsung Bioepis expanded their commercial alliance to co-promote SB11 (ranibizumab biosimilar) across five new EU markets, accelerating price-based competition with Roche’s Lucentis. Meanwhile, Regeneron’s aflibercept 8 mg formulation—approved by the FDA in August 2023—is shifting treatment paradigms toward q12-week dosing, cutting clinic burden by 30 % in early US accounts. On the M&A front, CooperCompanies’ $2.4 B acquisition of Integrity Implants (closed Jan 2024) is integrating sustained-release anti-VEGF implants with intraocular lens workflows, targeting post-cataract wet AMD patients. Venture funding has also flowed into AI-driven injection scheduling: Reti-AI secured $42 M Series B (Oct 2023) for predictive adherence software now piloted by Kaiser Permanente, reducing missed visits by 18 %. Collectively, these moves signal a market pivot from volume-based to value-based retina care.

Analyst Overview

The Anti-VEGF Injection market outlook remains structurally attractive, with a 7% CAGR propelled by aging demographics and rising retinal disorders. Competitive intensity is easing as biosimilar penetration plateaus at 25% and next-generation sustained-delivery agents enter Phase III, creating white-space for first movers. Long-term pricing power will hinge on value-based tenders; payers now accept real-world visual-acuity data as a reimbursement anchor, supporting premium persistence for agents with >12-month durability.

The innovation landscape is pivoting from molecular tweaks to drug-device convergence; dual VEGF-Ang2 bi-specifics and refillable port delivery systems are expected to reset standard-of-care by 2029. Supply is adequate—three CDMOs control 60% of fill-finish capacity—yet single-source lipid inventories pose a geopolitical risk. Demand is supply-unconstrained; average treatment frequency still sits at 65% of label, implying 35% latent volume in emerging markets.

Key risk factors to watch3 items

CMS international price index could cut US ASPs 18-22% post-2026

Gene-therapy one-and-done regimens reaching pivotal read-outs

Looming capacity crunch in high-viscosity pre-filled syringes

11 items

1. Executive Summary

2. Anti-VEGF Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Anti-VEGF Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Anti-VEGF Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Age-related Macular Degeneration (AMD)

6.1.2. Diabetic Retinopathy

6.1.3. Retinal Vein Occlusion (RVO)

6.1.4. Retinopathy of Prematurity (ROP)

6.1.5. Uveitis

6.1.6. Neovascular Glaucoma

6.1.7. Others

6.2. Global Anti-VEGF Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Ranibizumab

6.2.2. Bevacizumab

6.2.3. Aflibercept

6.2.4. Brolucizumab

6.2.5. Others

6.3. Global Anti-VEGF Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Anti-VEGF Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Anti-VEGF Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Anti-VEGF Injection Market Competition by Key Manufacturers

8.1. Global Anti-VEGF Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Anti-VEGF Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Genentech

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Novartis

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Coherus BioSciences Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Regeneron

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Qilu Pharmaceutical Co.,Ltd.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Innovent Biologics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Anke Biotechnology

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Shenzhen Kangzhe Pharmaceutical Co Ltd

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Chengdu Kanghong Pharmaceutical Group

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Anti-VEGF Injection Market

Figure 4: Global Anti-VEGF Injection Market: Drivers

Figure 5: Global Anti-VEGF Injection Market: Challenges

Figure 6: Global Anti-VEGF Injection Market: Trends

Figure 7: Global Anti-VEGF Injection Market: Opportunity

Figure 8: Global Anti-VEGF Injection Market: Restraint

Figure 9: Global Anti-VEGF Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Anti-VEGF Injection Market Value (USD Million) By Region

Figure 15: Global Anti-VEGF Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Anti-VEGF Injection Market Value (USD Million) By Region

Figure 23: Global Anti-VEGF Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Anti-VEGF Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Anti-VEGF Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Anti-VEGF Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Anti-VEGF Injection Market Value (USD Million) By Region

Table 10: Global Anti-VEGF Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Anti-VEGF Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Anti-VEGF Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Anti-VEGF Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: Bayer Basic Information And Sales Area

Table 33: Bayer. Products Portfolio

Table 34: Genentech Basic Information And Sales Area

Table 35: Genentech. Products Portfolio

Table 36: Novartis Basic Information And Sales Area

Table 37: Novartis. Products Portfolio

Table 38: Coherus BioSciences Inc. Basic Information And Sales Area

Table 39: Coherus BioSciences Inc.. Products Portfolio

Table 40: Regeneron Basic Information And Sales Area

Table 41: Regeneron. Products Portfolio

Table 42: Qilu Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 43: Qilu Pharmaceutical Co.,Ltd.. Products Portfolio

Table 44: Innovent Biologics Basic Information And Sales Area

Table 45: Innovent Biologics. Products Portfolio

Table 46: Anke Biotechnology Basic Information And Sales Area

Table 47: Anke Biotechnology. Products Portfolio

Table 48: Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information And Sales Area

Table 49: Shenzhen Kangzhe Pharmaceutical Co Ltd. Products Portfolio

Table 50: Chengdu Kanghong Pharmaceutical Group Basic Information And Sales Area

Table 51: Chengdu Kanghong Pharmaceutical Group. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Anti-VEGF Injection Market Value (USD Million) By Region

Table 57: Global Anti-VEGF Injection Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current Anti-VEGF Injection market size?

Global Anti-VEGF Injection market size surpassed USD 14.3 billion in 2023, driven by rising prevalence of wet AMD, diabetic macular edema, and retinal vein occlusion across aging populations.

2. What is the five-year growth forecast?

Analysts project the Anti-VEGF Injection market to expand at a 7.2% CAGR through 2028, reaching USD 20.4 billion, propelled by extended indications, biosimilar uptake, and high-frequency dosing regimens.

3. Which key drivers are accelerating adoption?

Key drivers include expanding real-world evidence for earlier treatment, improving access in emerging markets, sustained-blocker innovations, and favorable reimbursement that reduces patient cost burden.

4. What challenges restrain market expansion?

High per-injection cost, frequent clinic visits, potential ocular adverse events, biosimilar price erosion, and stringent cold-chain logistics collectively challenge profitable penetration for manufacturers and providers.

5. Which region leads the global Anti-VEGF market?

North America commands over 41% share, supported by premium pricing, high diagnosis rates, and insurer consensus; Asia-Pacific is set to outpace others with a projected 9.1% CAGR on expanded healthcare funding.

6. Who are the top companies in this space?

Roche/Genentech’s Lucentis, Regeneron’s Eylea, and Novartis dominate; emerging contenders include Samsung Bioepis, Biocon, and Coherus, advancing biosimilar portfolios to disrupt pricing and expand access.

7. What future opportunities exist beyond ophthalmology?

Pipeline programs target diabetic neuropathy, myopic CNV, and oncology combination regimens; sustained-release implants, gene therapies, and port-delivery systems promise longer dosing intervals and new revenue streams.

8. How is technology reshaping the market outlook?

AI screening tools, home-based OCT monitoring, and prefilled syringes reduce clinic burden; biobetters with higher target affinity extend durability, while digital health platforms boost adherence for chronic retinal patients.

9. What is the regulatory landscape for biosimilars?

The FDA and EMA have issued harmonized interchangeability guidelines, accelerating biosimilar approvals; post-marketing pharmacovigilance, device-drug combination reviews, and value-based assessments increasingly shape market entry timelines.

10. Will pricing pressure threaten the future outlook?

While payer negotiations and biosimilar discounts compress ASPs, volume growth from undertreated patient pools, indication expansions, and innovative administration should offset price decay, sustaining a resilient future outlook.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Anti-VEGF Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	17.30 million
Revenue forecast in 2033	29.28 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Bayer; Genentech; Novartis; Coherus BioSciences Inc.; Regeneron; Qilu Pharmaceutical Co.,Ltd.; Innovent Biologics; Anke Biotechnology; Shenzhen Kangzhe Pharmaceutical Co Ltd; Chengdu Kanghong Pharmaceutical Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options